Cargando…

Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up

This prospective multicentre study assesses long-term impact of genetic testing for breast/ovarian cancer predisposition in a clinical cohort. Areas evaluated include risk management, distress and insurance problems 3 years post-testing. Participants are adults unaffected with cancer from families w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foster, C, Watson, M, Eeles, R, Eccles, D, Ashley, S, Davidson, R, Mackay, J, Morrison, P J, Hopwood, P, Evans, D G R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360079/ https://www.ncbi.nlm.nih.gov/pubmed/17285126 http://dx.doi.org/10.1038/sj.bjc.6603610

Ejemplares similares

Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort
por: Watson, M, et al.
Publicado: (2004)

Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort
por: Foster, C, et al.
Publicado: (2002)

Feasibility of familial PSA screening: psychosocial issues and screening adherence
por: Sweetman, J, et al.
Publicado: (2006)

BRCA1 polymorphisms.
por: Campbell, I. G., et al.
Publicado: (1997)

BRCA1, BRCA2 and their possible function in DNA damage response
por: Kote-Jarai, Z, et al.
Publicado: (1999)

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial
por: Kote-Jarai, Z, et al.
Publicado: (2000)

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
por: Mitra, A, et al.
Publicado: (2008)

Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study
por: Girardi, Fabio, et al.
Publicado: (2018)

A randomised comparison of UK genetic risk counselling services for familial cancer: psychosocial outcomes
por: Hopwood, P, et al.
Publicado: (2004)

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
por: Evans, D G R, et al.
Publicado: (2010)

A novel tumour-based test to identify breast cancer due to BRCA1 and BRCA2 mutations
por: An, Q, et al.
Publicado: (2010)

Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers
por: McCrorie, Alan D, et al.
Publicado: (2020)

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Metcalfe, K, et al.
Publicado: (2011)

Management of Breast Cancer in BRCA1/2 Mutation Carriers
por: Eeles, R. A., et al.
Publicado: (1999)

Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers
por: Eeles, Rosalind A
Publicado: (2000)

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study
por: Hermsen, B B J, et al.
Publicado: (2007)

The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage
por: Howell, S J, et al.
Publicado: (2009)

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
por: Bancroft, Elizabeth K., et al.
Publicado: (2018)

Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT
por: Challberg, J, et al.
Publicado: (2011)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Developments in Clinical Practice: Follow up Clinic for BRCA Mutation Carriers: a Case Study Highlighting the "Virtual Clinic"
por: Ardern-Jones, Audrey, et al.
Publicado: (2004)

BRCA1 mutations in southern England.
por: Eccles, D. M., et al.
Publicado: (1998)

Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing
por: Fallowfield, Lesley, et al.
Publicado: (2022)

Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives
por: Ardern-Jones, Audrey, et al.
Publicado: (2010)

Understanding of BRCA VUS genetic results by breast cancer specialists
por: Eccles, B. K., et al.
Publicado: (2015)

Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up
por: Creak, A, et al.
Publicado: (2013)

The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk
por: Melia, J, et al.
Publicado: (2006)

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
por: van Sprundel, T C, et al.
Publicado: (2005)

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
por: Golan, T, et al.
Publicado: (2014)

UK BRCA mutation testing in patients with ovarian cancer
por: George, Angela
Publicado: (2015)

BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland.
por: Mullen, P., et al.
Publicado: (1997)

A descriptive study of UK cancer genetics services: an emerging clinical response to the new genetics
por: Wonderling, D, et al.
Publicado: (2001)

Long-term results of screening with magnetic resonance imaging in women with BRCA mutations
por: Passaperuma, K, et al.
Publicado: (2012)

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
por: Osorio, A, et al.
Publicado: (2011)

Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers
por: Antoniou, Antonis C, et al.
Publicado: (2006)

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
por: Copson, Ellen R, et al.
Publicado: (2018)

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers
por: Kadouri, L, et al.
Publicado: (2004)

The UK colorectal cancer screening pilot: results of the second round of screening in England
por: Weller, D, et al.
Publicado: (2007)

Measures of socioeconomic status and self-reported glaucoma in the UK Biobank cohort
por: Shweikh, Y, et al.
Publicado: (2015)

Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness
por: de Bock, G H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i4snhfit74i1d66dbnp0rq97qq